It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Stage IV Non-Small Cell Lung Cancer

Clinical Trial Title: 
A randomized two arm phase II trial of pembrolizumab alone or sequentially following single fraction non-ablative radiation to one of the target lesions, in previously treated patients with stage IV NSCLC.
Clinical Trial Protocol ID: 
17011605
Clinical Trial Investigator Name: 
Gaurav Marwaha, MD
Clinical Trial Protocol Description: 

This study looks at patients with advanced lung cancer. Participants in this study will be randomized into two groups. The first group will have radiation plus a drug (pembrolizumab). The second group will have only the drug (pembrolizumab). Tumors of participants will be measured to see if the addition of radiation changes the growth of the tumor compared to the drug alone.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have measurable disease based on RECIST 1.1.
  • Are willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.
  • Demonstrate adequate organ function.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Phone: 
(312) 942-8892
Contact Name: 
Jean Gibson, RN, BSN